In contrast to the results of Lukac et al., 2023, who used primary breast cancer cases and compared it with their multidisciplinary tumor board recommendation, we found the HER-2 treatment recommendation to be the most reliable one [11]. Here, ERBB2 is linked to breast carcinoma.